Biochemical Institute, Christian-Albrechts-University Kiel, Germany.
FEBS Lett. 2022 Mar;596(5):534-556. doi: 10.1002/1873-3468.14225. Epub 2021 Nov 18.
Systemic inflammatory disorders (SIDs) comprise a broad range of diseases characterized by dysregulated excessive innate immune responses. Severe forms of SIDs can lead to organ failure and death, and their increasing incidence represents a major issue for the healthcare system. Protease-mediated ectodomain shedding of cytokines and their receptors represents a central mechanism in the regulation of inflammatory responses. The metalloprotease A disintegrin and metalloproteinase (ADAM) 17 is the best-characterized ectodomain sheddase capable of releasing TNF-α and soluble IL-6 receptor, which are decisive factors of systemic inflammation. Recently, meprin metalloproteases were also identified as IL-6 receptor sheddases and activators of the pro-inflammatory cytokines IL-1β and IL-18. In different mouse models of SID, particularly those mimicking a sepsis-like phenotype, ADAM17 and meprins have been found to promote disease progression. In this review, we summarize the role of ADAM10, ADAM17, and meprins in the onset and progression of sepsis and discuss their potential as therapeutic targets.
系统性炎症障碍(SIDs)包括一系列广泛的疾病,其特征是先天免疫反应失调和过度活跃。严重形式的 SIDs 可导致器官衰竭和死亡,其发病率的增加是医疗保健系统面临的一个主要问题。蛋白酶介导的细胞因子及其受体的细胞外结构域脱落是调节炎症反应的一个核心机制。金属蛋白酶 A 分解素和金属蛋白酶(ADAM)17 是最具特征性的能够释放 TNF-α 和可溶性 IL-6 受体的细胞外结构域脱落酶,这两个因子是全身性炎症的决定性因素。最近,也发现 meprin 金属蛋白酶是 IL-6 受体脱落酶和促炎细胞因子 IL-1β 和 IL-18 的激活剂。在不同的 SID 小鼠模型中,特别是模拟脓毒症样表型的模型中,ADAM17 和 meprins 被发现可促进疾病进展。在这篇综述中,我们总结了 ADAM10、ADAM17 和 meprin 在脓毒症发病和进展中的作用,并讨论了它们作为治疗靶点的潜力。